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Abstract
Cardiomyopathies constitute a heterogeneous group of heart diseases. In fact, 
cardiomyopathies is a major cause of death either as end-stage heart failure or sud-
den cardiac death. Even though prognosis is, in many cases, poor there are several 
approaches to optimal disease management, which improves outcome and implies 
better quality of life including reduced risk of hospitalization. Differentiation of 
underlying etiology in individual cases of cardiomyopathies requires careful clinical 
evaluation. Echocardiography is the cornerstone in initial evaluation and follow-
up but cardiac magnetic resonance provides additional value. ECG, biomarkers, 
detailed history taking and extracardiac features may provide clues to less common 
entities. While forty years ago cardiomyopathy was defined as heart muscle disease 
of unknown origin, the underlying pathophysiology has now been elucidated. 
Indeed, the last decades the genetic explanations have evolved. Advanced treatment 
with pacemakers, including cardiac resynchronization, implantable defibrillators, 
and mechanical devices in the most severe cases are nowadays available for many 
patients. The evidence-based pharmacological approach to heart failure provides 
multiple interaction of pathophysiological pathways and has improved outcome. In 
selected cases specific agents are indicated why differential diagnosis is crucial and 
the genetic link imply cascade screening. This chapter aims to present a comprehen-
sive overview of the cardiomyopathies, categorized into: dilated-, hypertrophic-, 
restrictive-, arrhythmogenic and unclassified cardiomyopathy.
Keywords: arrhythmogenic cardiomyopathy, cardiomyopathy, dilated 
cardiomyopathy, heart failure, hypertrophic cardiomyopathy, left ventricular 
non-compaction, restrictive cardiomyopathy, sudden cardiac death, takotsubo 
cardiomyopathy
1. Introduction
The term cardiomyopathy was introduced by Brigden in 1957, to describe isolated 
noncoronary myocardial disease [1]. In 1980 the World Health Organization 
(WHO) released a document defining cardiomyopathies as “heart muscle diseases 
of unknown cause” [2]. Since then the understanding of these entities has grown 
considerably, and although some are deemed idiopathic, the underlying etiology 
of other cardiomyopathies have been elucidated. In 2008, the European Society of 
Cardiology (ESC) used the following definition of cardiomyopathy in their position 
statement:
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“A myocardial disorder in which the heart muscle is structurally and function-
ally abnormal, in the absence of coronary artery disease, hypertension, valvular 
disease and congenital heart disease sufficient to cause the observed myocardial 
abnormality [3].”
Many cardiomyopathies are of genetic origin [4], and the inheritance pattern 
is most often autosomal dominant, although autosomal recessive and X-linked 
inheritance patterns are encountered [5]. Non-familial forms include, among 
others, cardiomyopathy secondary to myocarditis caused by toxic or infectious 
agents [3, 6].
Terminology has historically been a challenge for many of the cardiomyopathies; 
takotsubo cardiomyopathy has acquired at least 75 different names [7] and for 
hypertrophic cardiomyopathy (HCM) that number exceeds 80 [8]. The goal of 
this chapter is to use the most established nomenclature, while in cases when the 
preferred term is less clear, it will be addressed.
2. Classification
Several attempts have been made to classify the cardiomyopathies. One classifi-
cation was suggested by Goodwin in 1961 [9], which described three clinical types, 
according to the effect the disease has on the heart’s function: congestive, obstruc-
tive, and constrictive. These categories are still in use, but are now termed dilated, 
hypertrophic, and restrictive, respectively [10]. In the 1980 report by the WHO [2], 
three distinct conditions were described: dilated-, hypertrophic- and restrictive 
cardiomyopathy. In addition to these forms WHO included unclassified cardio-
myopathy, covering the cases that did not fit in any of the other groups. Specific 
heart muscle disease, including, among others, conditions with infectious and 
metabolic etiology, was not considered to belong to the concept of cardiomyopathy. 
As the understanding of the pathogenesis and etiology grew, this classification was 
updated 15 years later - now with the addition of arrhythmogenic cardiomyopa-
thy (ACM), at the time called arrhythmogenic right ventricular cardiomyopathy 
(ARVC), and the term specific cardiomyopathies replacing specific heart muscle 
disease [11].
In 2006 the American Heart Association (AHA) proposed a new classification, 
stating that the identification of several new diseases, diagnostic advancements 
and precise knowledge of causation called for an updated version [6]. The dilated-
hypertrophic-restrictive classification, was considered limited in several regards. 
For example, mixing anatomical descriptions (hypertrophic and dilated) with 
one that is merely functional (restrictive), can result in one disease belonging in 
two categories. Furthermore, remodeling can cause a disease to develop from one 
category into another during its natural course. Instead, they propose a division of 
cardiomyopathies into two groups: primary and secondary. Primary cardiomyopa-
thies include those that solely, or predominantly, affect the myocardium. Secondary 
cardiomyopathies replace the term specific cardiomyopathies, hence including 
pathology of the heart muscle caused by systemic disorders. The two groups are 
further divided into categories based on etiology. The AHA also includes ion chan-
nelopathies as a cardiomyopathy, contrary to former classifications.
The ESC also suggested a classification two years later, aiming for a more 
clinically oriented system based on morphology and function [3]. This position 
statement proposes five categories: dilated-, hypertrophic-, restrictive-, arrhyth-
mogenic- and unclassified cardiomyopathy. Each category is then sub-classified as 
familial or non-familial (Figure 1). As opposed to the AHA, channelopathies and 
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conduction disorders were not considered cardiomyopathies. Neither in the classi-
fication system developed by the AHA nor the ESC, myocardial dysfunction caused 
by valvular, coronary, hypertensive or congenital heart disease, is considered as 
cardiomyopathy [4].
Lastly, a phenotype–genotype nomenclature, the MOGE(S) classification was 
suggested [4]. The letters each describe a feature of the cardiomyopathic condition 
where M stands for morphofunctional characteristic, O for organ involvement, G 
for genetic or familial inheritance pattern, and E for etiology. The S is optional, and 
refers to functional status.




Dilated cardiomyopathy (DCM) involves a dilated left ventricle with impaired 
left ventricular systolic function not solely explained by abnormal loading condi-
tions or coronary artery disease [13] (Figure 2). Left ventricular dilatation is 
defined as left ventricular end-diastolic volume or diameter that is >2 standard 
deviations from normal according to nomograms corrected for body surface area, 
age, and sex [13]. In some cases, dilatation and dysfunction of the right ventricle 
may occur as well [13]. It can be of genetic origin or can be attributed to non-genetic 
factors. To be categorized as familial, DCM has to be diagnosed in the proband and 
in at least on first- or second-degree relative [13].
3.2 Clinical features
DCM can lead to progressive heart failure and arrhythmias, and is associated 
with an increased risk of sudden cardiac death (SCD) [10]. Besides ventricular 
arrhythmias that may be fatal, atrioventricular block, atrial fibrillation and supra-
ventricular tachycardia (both with and without preexcitation) may also occur 
[15]. Idiopathic or familial DCM is usually first diagnosed in patients between 20 
and 50 years of age [16]. The most common presentation at diagnosis is related to 
congestive heart failure symptoms [17].
Figure 1. 
Classification of cardiomyopathies as proposed by the European Society of Cardiology [3]. Cardiomyopathies 
are first classified according to morphology and function, then based on whether the disease is familial or non-
familial, and lastly depending on either known disease causing mutation or pathophysiological mechanism. 
Image from Mattsson et al. [12]. Published by IntechOpen under open access https://creativecommons.org/
licenses/by/3.0/.
Cardiomyopathy - Disease of the Heart Muscle
4
3.3 Epidemiology
DCM is the leading cause of heart transplantation and the third most common 
reason for heart failure [6]. The estimated prevalence is 1:2500 [6], and it more 
commonly affects men than women [18].
3.4 Etiology
There are several known causes for the sporadic form of DCM; toxins (for 
example ethanol, lead and cocaine), metabolic abnormalities (including hypothy-
roidism and thiamine deficiency), neuromuscular disorders (for example Duchenne 
muscular dystrophy) and inflammatory or infectious (viral, bacterial, fungal) con-
ditions are all among them [16]. Chagas’ disease, caused by the protozoan parasite 
Trypanosoma cruzi, is an example of an infectious disease that can lead to DCM [19]. 
WHO estimated that 10 million people were infected in 2009, and the cardiac form 
affects up to 30% [20]. Peripartum cardiomyopathy is a form of acquired DCM [15].
Approximately 20–35% of DCM cases are familial, while the most common 
inheritance pattern is autosomal dominant; X-linked, autosomal recessive and 
mitochondrial patterns occur seldom [6]. Mutations in genes coding cytoskeletal 
and sarcomeric proteins are the most common. Mutations in the gene coding for the 
protein titin is the most common, accounting for up to a quarter of known muta-
tions [21]. Mutations in most genes result in similar phenotypes, thus broad gene 
panels are required. However, among patients who have atrioventricular block, 
mutations in the gene coding for lamin A/C (LMNA) are the most common [15]. 
Between 5 and 10% of patients with DCM have disease-causing LMNA mutation 
[18]. When no etiology is identified, DCM is categorized as idiopathic [16].
3.5 Treatment
DCM is treated similarly to other forms of heart failure with reduced ejection 
fraction (EF) [10]. Initial medical treatment consists of angiotensin-converting 
enzyme (ACE)-inhibitors or angiotensin receptor blockers (ARB), beta-blockers, and 
mineralocorticoid receptor antagonists (MRA). In patients who are still symptomatic 
Figure 2. 
Echocardiography that shows dilatation of the left ventricle and signs of diastolic dysfunction. Image adapted 
from Jamil et al. [14]. Published by IntechOpen under open access https://creativecommons.org/licenses/by/3.0/.
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and have an EF ≤35% or, the ACE-inhibitor or ARB should be replaced by an angio-
tensin receptor neprilysin inhibitor. Cardiac resynchronization therapy should be 
considered in patients who have a QRS duration ≥150 ms, or QRS duration ≥130 ms 
and left bundle branch block. Ivabradine should be considered for patients in sinus 
rhythm with pulse above 70 beats per minute. Heart transplantation may be consid-
ered in end-stage heart failure, and left ventricular assist devices can be used a bridge 
to transplantation, or as a permanent treatment [22]. The sodium-glucose transporter 
protein 2 inhibitor dapaglifozin has been associated with a reduced cardiovascular 
mortality and a reduced risk of worsening heart failure in patients with heart failure 
with reduced EF, in both patients with diabetes type 2 [23] and non-diabetics [24].
In patients who have experienced a hemodynamically not tolerated ventricular 
arrhythmia, implantable cardioverter defibrillator (ICD) therapy is recommended. 
Furthermore, an ICD is recommended for those with symptomatic heart failure 
(New York Heart Association [NYHA] class II-III) with reduced EF of ≤35%, fol-
lowing at least three months of optimal medical therapy. These recommendations 
apply if the expected survival exceeds one year with good functional status. In the 
case of an established disease-causing LMNA mutation and clinical risk factors, an 
ICD should also be considered [18].
4. Hypertrophic cardiomyopathy
4.1 Definition
The ESC defines HCM as “presence of increased left ventricular wall thickness 
that is not solely explained by abnormal loading conditions” [25]. More precisely, 
a wall thickness of ≥15 mm in at least one left ventricular myocardial segment is 
required for the diagnosis of HCM in adults (Figure 3). In borderline cases with 
13–14 mm, careful evaluation, including family history, is needed; if a first-degree 
relative had definite HCM the diagnosis is made [25]. Notably, the American guide-
lines from 2011 hold another position. They recognize HCM as a clinical entity “… 
characterized by unexplained left ventricular hypertrophy associated with nondi-
lated ventricular chambers in the absence of another cardiac or systematic disease 
that itself would be capable of producing the magnitude of hypertrophy …” [26]. 
There are several diseases, especially in children and young adults, which mimic 
Figure 3. 
Echocardiography showing septal hypertrophy in a patient with HCM. Image used with permission from the 
author Peter Magnusson.
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hypertrophy caused by sarcomeric protein mutations. The American guidelines 
emphasize that these conditions, so-called phenocopies, should not be included in 
the term HCM [26].
In the American definition of HCM, there are other groups of diseases and 
conditions that present with hypertrophy, that are not included in the term HCM. 
These can be categorized based on cellular mechanisms, i.e. neuromuscular, mito-
chondrial, and metabolic disorders (glycogen storage, carnitine, lysosomal storage). 
Among the metabolic disorders are glycogen storage diseases such as Danon disease, 
Pompe disease, and Anderson-Fabry disease. Malformation syndromes are typically 
diagnosed in pediatric settings; LEOPARD (lentiges, ECG abnormalities, ocular 
hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, and 
sensorineural deafness), Noonan syndrome (facial features, short height, congeni-
tal heart disease, bleeding problems, and skeletal malformations), and others.
4.2 Clinical features
Typical symptoms include dyspnea, palpitations, syncope and chest discomfort, 
but many patients lack specific symptoms altogether [25]. Indeed, the majority 
are likely never diagnosed [27]. Chest discomfort sometimes occurs at rest or 
during exertion, postprandial or following alcohol consumption. It is uncommon 
for people with HCM to present with decompensated heart failure, but symptoms 
of chronic heart failure are often present. The pathology varies, from diastolic 
dysfunction with preserved EF to systolic left ventricular dysfunction or left 
ventricular outflow tract obstruction. Among those with left ventricular outflow 
tract obstruction, a systolic murmur can sometimes be auscultated at the left sternal 
edge [25].
As for syncope as a symptom of HCM, the cause can be, among others, complete 
heart block, sinus node dysfunction, or ventricular tachycardia [25]. Causes that 
are not directly related to the conduction system include left ventricular outflow 
obstruction, diastolic dysfunction and altered baroreflex mechanisms [28].
According to U.K. data on 357 sudden death cases in athletes the mean age 
was 29 years and the vast majority males (92%) [29]. Sudden arrhythmic death 
was the most common cause of death, and HCM accounted for 6% of all deaths. 
Interestingly, 40% of these athletes died during resting conditions. An Italian 
sample of 54 fatal cases (mean age 27 years; 76% men) revealed HCM in 9.2% [30].
4.3 Epidemiology
In adults, the prevalence of HCM is frequently reported as 1:500 [31], but a 
recent Icelandic study reported 1:1600 [32]. On the other hand an extremely high 
prevalence (about 1:200) was claimed when both phenotypes and genotypes were 
included based on cohorts from expert centers [33]. Moreover, misclassifications 
are common in HCM [34].
4.4 Etiology
HCM is often explained by a genetic disease (in approximately half of the cases); 
a mutation in cardiac sarcomeric protein genes, with an autosomal dominant pat-
tern of inheritance. X-linked inheritance is less common, and autosomal recessive is 
the most uncommon pattern. Other genetic disorders, such as inherited neuromus-
cular diseases or chromosome abnormalities, are the underlying reason for 5–10% 
of adult cases. Non-genetic causes of HCM include amyloidosis and drug toxicity. 
The etiology of the remaining 25–30% is unknown [25].
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4.5 Treatment
Patients with symptomatic left ventricular outflow tract obstruction should 
initially receive beta-blockers in the highest tolerated dose. If symptoms persist, the 
next step is adding disopyramide. For those who cannot tolerate beta-blockers or 
when they are ineffective, verapamil is an option. Loop- or thiazide diuretics may 
be used in low doses to improve dyspnea. For patients with a left ventricle outflow 
tract obstruction gradient exceeding 50 mmHg, persistent symptoms (moderate to 
severe) and/or repeated syncope upon exertion, despite medical therapy, invasive 
treatment with septal myectomy or alcohol septal ablation should be considered. 
For symptomatic elderly patients who are not candidates for invasive treatment, 
permanent pacing with short atrioventricular interval may be considered [25].
For those without left ventricle outflow tract obstruction who have symptoms of 
heart failure but a normal EF, beta-blockers, verapamil (or diltiazem) and careful 
administration of diuretics is indicated. Renin-angiotensin-aldosterone system 
inhibition is not extensively studied in HCM patients, but the ESC recommends the 
use of beta-blockers, ACE-inhibitors, ARB, MRA and diuretics for HCM patients 
with symptoms of heart failure and reduced EF, in line with their general recom-
mendations for management of chronic heart failure [25].
Pacemaker therapy in bradycardia is recommended according to the general ESC 
guidelines [25]. When it comes to ICD treatment, patients with HCM who have not 
experienced ventricular fibrillation or ventricular tachycardia with hemodynamic 
compromise, may be candidates for ICD based on the 5-year risk, determined by 
the validated ESC calculator HCM Risk-SCD [18, 35].
5. Restrictive cardiomyopathy
5.1 Definition
Restrictive cardiomyopathy (RCM) is defined as the presence of restrictive 
filling in combination with normal or decreased diastolic ventricular volume in one 
or both ventricles. The systolic function is normal or only slightly impaired [11]. 
Different underlying causes may result in normal or increased wall thickness [36].
5.2 Clinical features
Since either one or both ventricles can be affected, both left and right ventricu-
lar failure may occur. Symptoms of right ventricular failure generally predominate 
(ascites, peripheral edema), but breathlessness as a symptom of left-sided heart 
failure occurs as well [36]. In an advanced stage of the disease all signs of heart 
failure, except cardiomegaly, develop [36]. Certain findings are more common 
with specific etiologies, such as conduction disturbances in amyloidosis [37] 
and sarcoidosis, and atrial fibrillation in idiopathic RCM and amyloidosis [36]. 
Overall, conduction disturbances as well as arrhythmias occur frequently [38]. 
Distinguishing RCM from constrictive pericarditis (which presents with similar 
findings) can be challenging, but is important due to the differences in prognosis 
and management [36, 39].
5.3 Epidemiology
Epidemiologic data is scarce, but RCM has been described as the least common 
cardiomyopathy [36].
Cardiomyopathy - Disease of the Heart Muscle
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5.4 Etiology
RCM can be idiopathic or familial. Furthermore, there are a number of different 
local or systemic disorders that can cause RCM [36]. Endomyocardial fibrosis is 
believed to be the most common cause of RCM [40]. It is endemic to parts of Africa, 
Asia, South and Central America, but can occur elsewhere sporadically [36]. It pre-
dominantly affects children and adolescents. The etiology is not known [40]. Other 
endomyocardial causes of RCM include radiation and metastatic cancers. Infiltrative 
diseases causing RCM include cardiac amyloidosis and sarcoidosis. Finally, RCM can 
develop due to storage diseases, such as hemochromatosis [36].
5.5 Treatment
Prognosis is poor, especially in children, where the 2-year survival rate is less 
than 50% [41]. Treatment serves to manage heart failure and, if possible, treat the 
underlying disease [38]. Venous congestion is treated with diuretics, used with cau-
tion as to avoid reducing filling pressures and decrease cardiac output [36]. Since 
atrial fibrillation can increase diastolic dysfunction, maintaining sinus rhythm is 
of importance and antiarrhythmic agents may be indicated [36]. Beta-blockers 
and calcium channel blockers are sometimes not tolerated, and should be carefully 
introduced if needed. Regarding ACE-inhibitors and ARB, there is not much proof 
of benefit and they are not always tolerated, but can be considered [38]. Due to 
the propensity for thrombus to form in the left atrial appendage, anticoagulation 
may benefit most patients [36, 38]. Selected patients may be candidates for heart 
transplantation or left ventricular assist device [38].
6. Arrhythmogenic cardiomyopathy
6.1 Definition
In ACM, the ventricular myocytes are replaced by fibrofatty tissue [42]. The 
myocardial atrophy is progressive, starting in the epicardium, it becomes transmu-
ral with time and leads to wall thinning [42]. ACM was previously known as ARVC 
or ARVD where the D stands for dysplasia, which it was originally characterized 
as [42]. With time it has become apparent that there are variants where the left 
ventricle is more severely involved than the right, which is the reason some have 
suggested an updated terminology [42]. Notwithstanding, the fibrofatty tissue 
replacement often occurs in a “triangle of dysplasia”, involving the right ventricular 
inflow, outflow and apex [3]. In the 2008 classification by the ESC, the term ARVC 
is used. In 2019 the Heart Rhythm Society published a consensus statement on 
ACM, where ARVC and arrhythmogenic left ventricular cardiomyopathy were 
considered to be separate cardiomyopathies with specific phenotypes, under the 
umbrella of the term ACM [43].
In their 2008 classification, the ESC defines ARVC as dysfunction of the right 
ventricle, with or without left ventricular involvement, in the presence of histologi-
cal evidence and/or ECG abnormalities in accordance with published criteria [3]. 
These include, but are not limited to, epsilon waves in leads V1-V3, inverted T-waves 
in leads V1-V3 or beyond in people above 14 years of age in the absence of right 
bundle branch block and sustained or nonsustained ventricular tachycardia of left 
bundle-branch morphology with superior axis [44]. The diagnostic criteria for 
ARVC are subdivided into major and minor criteria, where diagnosis requires two 
major criteria, or one major criterion in combination with two minor criteria, or 
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four minor criteria from different categories. The categories are global or regional 
dysfunction and structural alterations, tissue characterization of walls, repolariza-
tion abnormalities, depolarization or conduction abnormalities, arrhythmias, and 
family history [44]. Variants of the disease, such as Naxos disease and Carvajal 
syndrome, albeit rare, present with a specific phenotype and are considered cardio-
cutaneous entities; they share the presentation and risk of common ARVC [45, 46].
6.2 Clinical features
The presentation of ACM varies greatly; while some patients are asymptomatic, 
others suffer from supraventricular arrhythmias, ventricular tachycardia, right-
heart failure [47], or even biventricular heart failure [48]. In addition to this, ACM 
is one of the most common causes for SCD among young people [42], and one 
study has reported that 10% of SCDs (in people between 1 and 65 years of age) can 
be attributed to ARVC [47]. A retrospective study found that among 130 patients 
with ARVC, overall mortality was primarily of cardiovascular origin, where heart 
failure accounted for two thirds of the cardiac deaths and SCD for the remaining 
one third [49].
6.3 Epidemiology
The prevalence of ARVC has been estimated to range between 1:1000 and 
1:5000 in adults [50, 51].
6.4 Etiology
ACM is usually familial, with an autosomal dominant pattern of inheritance. 
The majority of patients have at least one disease-causing variant of a gene coding 
for a desmosomal protein [43]. The protein plakoglobin is reported to be implicated 
in ACM, most notably in the autosomal recessive form Naxos disease [52]. Another 
autosomal recessive variant of ACM is Carvajal syndrome [46].
6.5 Treatment
Competitive exercise has been shown to increase the risk of SCD in adolescents 
and young adults five-fold [53], and frequent exercise increases the risk of ARVC 
diagnosis, ventricular arrhythmias and heart failure among carriers of desmosomal 
mutations [54]. Consequently, it is a class I recommendation from the ECS that 
patients with ARVC must refrain from competitive- and endurance sports, and a 
class IIa recommendation that they do not participate in any athletic activities (with 
the possible exception of recreational low-intensity sports) [48].
Regarding medical therapy, beta-blockers should be considered in all ARVC 
patients, and are specifically recommended for those with recurrent ventricular 
tachycardia or ICD shocks (either appropriate, or inappropriate shocks due to 
supraventricular tachycardias). Antiarrhythmic drugs can be used to prevent 
ventricular arrhythmias. Amiodarone, by itself or combined with beta-blockers, 
has been suggested by available evidence as the most effective alternative. It has not 
been proven to prevent SCD [48]. Patients who develop heart failure should receive 
standard medical treatment [48].
There is no proof that catheter ablation prevents SCD in ARVC, but it can reduce 
the recurrence of ventricular tachycardia. It is recommended in patients with inces-
sant ventricular tachycardia and those who experience frequent appropriate ICD 
shocks despite maximal tolerable medical therapy [48].
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Preventing SCD is the most important goal of treatment [42]. The only therapy 
that has been proven to be life-saving is ICD, but the benefit must be weighed 
against the significant morbidity due to inappropriate shocks and device-related 
complications [42]. Indications for ICD are based on risk stratification, where 
patients are divided into one of three categories based on their risk factors for major 
arrhythmic events. As a final option, when patients suffer from severe congestive 
heart failure unresponsive to other treatment, or recurrent ventricular tachycardia 
or -fibrillation despite ablation and/or ICD therapy, heart transplantation is recom-
mended [48].
Patients should be followed-up clinically and with ECG, echocardiography, 
24-h Holter monitoring, and exercise-testing at regular intervals throughout their 
lives [48].
7. Unclassified cardiomyopathy
In the 2008 position statement from the ESC regarding classification of the 
cardiomyopathies, left ventricular non-compaction (LVNC) and takotsubo cardio-
myopathy are regarded as unclassified cardiomyopathies [3]. Since this chapter is 
structurally based on the position statement, these two conditions will be briefly 
described. The group of cardiomyopathies that are deemed unclassified, however, 
has varied over time. In 1980, the WHO included, among others, endocardial 
fibroelastosis and Fiedler’s myocarditis [2]. 15 years later, when the updated clas-
sification by the WHO was published, non-compaction cardiomyopathy, systolic 
dysfunction with minimal dilatation and mitochondrial cardiomyopathies were 
added to the unclassified cardiomyopathies [11, 55]. The future most certainly holds 
exciting advances in this field, and it is not a stretch of the imagination to think that 
this category will continue to evolve in the years to come.
7.1 Takotsubo cardiomyopathy
7.1.1 Definition
Takotsubo cardiomyopathy was first described in 1990. The name refers to a 
Japanese octopus-trap that bears likeness to the end-systolic left ventriculogram 
seen in the condition [56]. Sometimes referred to as transient left ventricular apical 
ballooning syndrome, takotsubo cardiomyopathy leads to regional systolic dys-
function of the left ventricular apex and/or mid-ventricle. For diagnosis, coronary 
disease should be excluded by coronary angiography [3]. Since ST-segment eleva-
tion and positive troponin is seen in more than 80% of patients [57], the diagnosis 
is often not considered until after coronary angiography is performed. In their 
2016 position statement, the ESC refers to takotsubo as a syndrome rather than a 
cardiomyopathy, with the motivation that the diagnosis is based on a set of clini-
cal observations - which is what defines a clinical syndrome. Since the patients do 
not appear to have a primary heart muscle disorder, no common genetic etiology 
has been identified, and most recover fully - takotsubo is likely different from the 
primary cardiomyopathies [58].
7.1.2 Clinical features
The first symptom is usually chest pain, which affects most of the patients. 
The condition highly resembles an acute coronary syndrome. Dyspnea is another 
11
An Overview of the Cardiomyopathies
DOI: http://dx.doi.org/10.5772/intechopen.95568
common presentation [57]. Although the disease is generally considered benign, 
more than half of patients experience some form of complication [58]. Between 4% 
and 20% of patients develop cardiogenic shock [58], and 1.5% go into ventricular 
fibrillation [57]. Most patients have clear left ventricular dysfunction when they are 
admitted, but in weeks the cardiac function improves drastically [57]. Left ventricu-
lar EF usually recovers within three months, while ECG and elevated BNP levels may 
persist for up to a year or, sometimes, become permanent [58]. However, one ret-
rospective observational study has found that early and late mortality in takotsubo 
cardiomyopathy is similar to the numbers seen in acute myocardial infarction [59].
7.1.3 Epidemiology
It has been estimated that approximately 2% of ST-segment elevation myocar-
dial infarctions are in fact takotsubo cardiomyopathy. Out of all patients, most are 
post-menopausal women, about 90% [57].
7.1.4 Etiology
The exact pathophysiology is unknown, although several theories have been pre-
sented. Multivessel coronary vasospasm, coronary microvascular dysfunction and 
elevated levels of catecholamines leading to cardiotoxicity are found among these 
[57]. Often, the debut is preceded by emotional or physical stress, but in a minority 
of patients no such stressor can be identified [57]. Because of this, the term broken 
heart syndrome is sometimes used for the condition [60]. However, in a small 
number of patients takotsubo is triggered by a positive emotional experience [61].
7.1.5 Treatment
No randomized clinical trials that can form a basis for treatment recommenda-
tions exist. The ESC Heart Failure Association has proposed a risk stratification 
system, including among others age, systolic blood pressure, and pulmonary 
congestion, to be used for choosing the appropriate approach. In patients without 
complications and a left ventricular EF of over 45%, early discharge from hospital 
may be considered. Heart failure medications, including beta-blockers, should be 
considered in patients with an EF between 35 and 45%, who are otherwise at low 
risk. According to some experts, vasoactive drugs such as ACE inhibitors, should 
not be given to patients with a normal cardiac output, as takotsubo may be associ-
ated with low peripheral vascular resistance [58].
Higher risk patients (risk factors include, but are not limited to, age 75 or above, 
EF below 35%, and systolic blood pressure less than 110 mmHg) with takotsubo 
cardiomyopathy should be monitored for at least 72 hours after presentation 
with continuous ECG. It is recommended to avoid sympathomimetic drugs. Beta-
blockers may be considered in hemodynamically stable patients, and patients with 
tachyarrhythmias. Patients with a hemodynamically significant left ventricular 
outflow tract obstruction should be considered for treatment with a beta-blocker 
of selective alpha1-agonist. Cardiogenic shock in patients with takotsubo car-
diomyopathy can be managed with temporary left ventricular assist devices and 
extracorporeal membrane oxygenation, or low-dose levosimendan infusion. Other 
inotropes are generally contraindicated, owing to the possible worsening of status 
and outcome due to their activation of catecholamine receptors [58].
Low risk patients should be followed-up for 3 to 6 months, with cardiac imaging 
and a review of the medication [58].
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7.2 Left ventricular non-compaction
7.2.1 Definition
LVNC is characterized by deep intertrabecular recesses in the left ventricle 
[62], resulting in a “spongy” morphological appearance [6]. LNVC often leads to 
a thickened myocardial wall, due to thickening of the endocardial layer, but the 
epicardium is compacted and thin (Figure 4). Dilation of the left ventricle and 
systolic dysfunction occur in some patients [3]. In their 2008 classification, the 
ESC commented that it is unclear whether LVNC is a distinct cardiomyopathy or a 
morphology seen in several different cardiomyopathies. Echocardiographic diagno-
sis is based on the Jenni criteria consisting of four criteria: absence of other cardiac 
abnormalities, end-systolic ratio between non-compacted endocardial myocardium 
and compacted epicardial myocardium of >2, hyper-trabeculation localized to the 
apex/mid-inferior/mid-lateral areas, and color doppler with blood flow from the 
ventricle into deep intertrabecular recesses that do not communicate with coronary 
vessels [63].
7.2.2 Clinical features
The dominating clinical manifestations are heart failure, arrhythmias and 
embolism due to thrombi forming within the intertrabecular recesses, but the 
presentation varies and some patients are asymptomatic [65]. One study reports 
chronic atrial fibrillation in 26% of LVNC patients, and ventricular tachycardia 
in 41% [66]. In the same study, 50% of all deaths were SCD. Non-compaction of 
both ventricles has been reported [67], but since the right ventricular apex is often 
highly trabeculated, the distinction between normal and pathological patterns 
is difficult and the existence of right ventricular non-compaction is therefore 
 disputed [65, 66].
7.2.3 Epidemiology
The prevalence is unknown, and the results of studies vary. One echocardio-
graphic study estimated a prevalence in the general population of 0.05% [67], 
another prevalence estimation based on patients referred to an echocardiography 
laboratory was 0.014% [66].
Figure 4. 
A thick, non-compacted myocardium in the left ventricular wall. Transthoracic echocardiogram, during systole, 
apical long-axis view. Image from Mattsson et al. [64]. Published by BMC Cardiovascular Disorders under 
open access https://creativecommons.org/licenses/by/4.0/.
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7.2.4 Etiology
LVNC is believed to occur when compaction of the myocardial fibers and mesh-
work is arrested during intrauterine development [62]. Normally, the intertrabecu-
lar recesses seen in LVNC are transformed to capillaries during 5 to 8 weeks of fetal 
development [68]. Serial echocardiographic studies where LVNC was not diagnosed 
in the first echocardiogram, however, suggest that it could be an acquired condition. 
The fact that LVNC is associated with mutations in sarcomere protein genes found 
in patients with both DCM and HCM, is another reason to ask the question whether 
LVNC could develop later in life [69].
There are descriptions of both familial and non-familial cases, and LVNC can be 
isolated or associated with other congenital heart anomalies [6]. The disease is clas-
sified as a primary genetic cardiomyopathy by the AHA [6]. Apart from mutations 
in sarcomeric proteins, LVNC can be linked to mutations in mitochondrial, Z-disc 
or cytoskeletal proteins [69]. The predominant mode of inheritance is autosomal 
dominant with incomplete penetrance, but autosomal recessive and X-linked pat-
terns occur as well. Approximately one in four patients has a familial form [70].
7.2.5 Treatment
No specific treatment for LVNC exists [69]. Heart failure is treated with stan-
dard medical therapy. Yearly ambulatory ECGs for monitoring to assess rhythm 
disturbances, since these occur frequently in LVNC, should be performed [65]. In 
a long-term follow-up of 34 adult LVNC patients, thromboembolic complications 
were reported in 24%; thus the authors recommended that oral anticoagulation for 
all patients diagnosed with LVNC should be considered [66]. Another study found 
systemic embolization in 3 of their 8 patients [71]. In an article published in 2011, 
the authors recommend oral anticoagulation only in patients with an EF <40%, 
since they have never observed thromboembolic complications in a patient in sinus 
rhythm with a preserved EF [69]. There are no guidelines regarding anticoagulation 
in LVNC patients, and there is no general consensus in clinical practice [72].
8. Conclusions
The vast complexity that surrounds the diseases of the heart muscle can make 
the diagnosis and management of cardiomyopathy patients challenging. However, 
since the prevalence of heart failure and life-threatening arrhythmias is high among 
patients with cardiomyopathy it is crucial to correctly identify the patients and risk 
stratify. So far, as guidelines specific for heart muscle disease are not available for 
all its forms, treatment follows general guidelines for arrhythmias and heart failure. 
European or world-wide registries would offer most valuable insights and illumi-
nate the future management of cardiomyopathies.
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